acoramidis hydrochloride · Bridgebio Pharma · NDA 216540
Attruby
Earliest generic entry, as listed
16 Aug 2039
Blocked by patent: US 11260047, US 12005043, US 12539290.
Listed patents · 13 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11260047 | product | 16 Aug 2039 |
| US 12005043 | product, use U-4046 | 16 Aug 2039 |
| US 12539290 | product | 16 Aug 2039 |
| US 11058668 | use U-4046 | 22 Mar 2039 |
| US 12070449 | use U-4046 | 22 Mar 2039 |
| US 10513497 | substance | 16 Feb 2038 |
| US 11919865 | use U-4046 | 16 Feb 2038 |
| US 10398681 | product | 5 May 2031 |
| US 10842777 | use U-4046 | 5 May 2031 |
| US 8877795 | product | 5 May 2031 |
| US 9169214 | product, use U-4046 | 5 May 2031 |
| US 9642838 | substance, product | 5 May 2031 |
| US 9913826 | use U-4046 | 5 May 2031 |
Exclusivities · 2 unexpired
| ODE-506 | orphan drug (7 years) | 22 Nov 2031 |
| NCE | new chemical entity (5 years) | 22 Nov 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 216540 · 001 · RLD | tablet, oral | EQ 356MG BASE | 16 Aug 2039 |